​

Halozyme Therapeutics (HALO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HALO Stock Forecast

Halozyme Therapeutics stock forecast is as follows: an average price target of $52.00 (represents a 10.73% upside from HALO’s last price of $46.96) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

HALO Price Target

The average price target for Halozyme Therapeutics (HALO) is $52.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $52.00 to $52.00. This represents a potential 10.73% upside from HALO's last price of $46.96.

HALO Analyst Ratings

Buy

According to 9 Wall Street analysts, Halozyme Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for HALO stock is 0 'Strong Buy' (0.00%), 6 'Buy' (66.67%), 3 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Halozyme Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024Joseph CatanzaroPiper Sandler$52.00$46.7211.31%10.73%
Jun 07, 2024Mitchell KapoorH.C. Wainwright$65.00$51.4426.36%38.42%
Jun 07, 2024Joseph CatanzaroPiper Sandler$51.00$51.44-0.86%8.60%
Jun 07, 2024Mohit BansalWells Fargo$58.00$51.4412.75%23.51%
Jun 06, 2024Corinne JenkinsGoldman Sachs$44.00$51.44-14.46%-6.30%
Jan 11, 2023Leerink Partners$61.00$55.709.52%29.90%
Dec 21, 2022Morgan Stanley$65.00$58.6310.86%38.42%
Nov 28, 2022Wells Fargo$65.00$55.5317.04%38.42%
Nov 22, 2022J.P. Morgan$54.00$52.742.39%14.99%

The latest Halozyme Therapeutics stock forecast, released on Nov 15, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $52.00, which represents a 11.31% increase from the stock price at the time of the forecast ($46.72), and a 10.73% increase from HALO last price ($46.96).

Halozyme Therapeutics Price Target by Period

1M3M12M
# Anlaysts-15
Avg Price Target-$52.00$54.00
Last Closing Price$46.96$46.96$46.96
Upside/Downside-100.00%10.73%14.99%

In the current month, the average price target of Halozyme Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Halozyme Therapeutics's last price of $46.96. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024Piper SandlerNeutralNeutralHold
Nov 04, 2024Piper SandlerNeutralNeutralHold
Nov 01, 2024Leerink PartnersMarket PerformMarket PerformHold
Oct 18, 2024Cowen & Co.BuyBuyHold
Oct 07, 2024Wells FargoMarket OutperformEqual-WeightDowngrade
Oct 04, 2024H.C. WainwrightBuyBuyHold
Oct 04, 2024Goldman SachsUnderperformUnderperformHold
Sep 13, 2024Goldman SachsUnderperformUnderperformHold
Sep 13, 2024H.C. WainwrightBuyBuyHold
Aug 07, 2024Cowen & Co.BuyBuyHold
Aug 07, 2024Morgan StanleyOverweightOverweightHold
Jul 16, 2024Wells FargoMarket OutperformMarket OutperformHold
Jul 16, 2024Piper SandlerUnderperformUnderperformHold
Jun 25, 2024BenchmarkBuyBuyHold
Jun 24, 2024Piper SandlerUnderperformUnderperformHold
Jun 24, 2024Wells FargoMarket OutperformMarket OutperformHold
Jun 07, 2024Wells FargoOverweightOverweightHold
Jun 07, 2024H.C. WainwrightBuyBuyHold
Jun 06, 2024Piper SandlerOverweightNeutralDowngrade
Jun 06, 2024Goldman SachsNeutralNeutralHold
Jun 04, 2024JMP SecuritiesMarket OutperformMarket OutperformHold
Jun 04, 2024H.C. WainwrightUnderperformUnderperformHold
May 07, 2024JMP SecuritiesBuyBuyHold
Apr 16, 2024JMP SecuritiesBuyBuyHold
Feb 21, 2024Morgan StanleyMarket OutperformMarket OutperformHold
Feb 21, 2024JMP SecuritiesUnderperformUnderperformHold
Jan 18, 2024JMP SecuritiesUnderperformUnderperformHold
Jan 18, 2024Morgan StanleyMarket OutperformMarket OutperformHold
Dec 26, 2023Morgan StanleyBuyBuyHold
May 10, 2023Piper SandlerOverweightUpgrade
Jan 11, 2023SVB LeerinkOutperformOutperformHold
Dec 21, 2022Morgan StanleyOverweightOverweightHold
Dec 08, 2022BenchmarkBuyBuyHold
Nov 28, 2022Wells FargoOverweightInitialise

Halozyme Therapeutics's last stock rating was published by Piper Sandler on Nov 15, 2024. The company gave HALO a "Neutral" rating, the same as its previous rate.

Halozyme Therapeutics Financial Forecast

Halozyme Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$216.03M$221.04M$162.14M$181.50M$208.98M$152.37M$117.28M$102.00M$115.83M$136.46M$89.02M$121.70M$65.32M$55.22M$25.35M$53.66M$46.23M$39.15M$56.95M$30.87M$29.57M
Avg Forecast$307.25M$295.30M$278.00M$263.20M$294.15M$252.17M$204.94M$199.74M$231.00M$216.08M$199.95M$179.26M$192.05M$191.17M$138.63M$128.25M$101.54M$105.84M$104.12M$84.88M$120.01M$59.90M$66.68M$42.96M$56.93M$54.96M$42.76M$67.83M$35.78M$28.46M
High Forecast$317.85M$305.49M$287.59M$268.45M$317.57M$255.82M$204.94M$199.74M$237.20M$235.13M$206.85M$185.45M$198.68M$191.17M$138.63M$128.25M$101.54M$105.84M$104.12M$84.88M$120.01M$59.90M$66.68M$42.96M$56.93M$54.96M$42.76M$67.83M$42.93M$34.15M
Low Forecast$299.44M$287.80M$270.94M$259.97M$277.99M$248.52M$204.94M$199.74M$227.81M$198.56M$194.87M$174.71M$187.17M$191.17M$138.63M$128.25M$101.54M$105.84M$104.12M$84.88M$120.01M$59.90M$66.68M$42.96M$56.93M$54.96M$42.76M$67.83M$28.62M$22.77M
# Analysts11136333685443435454599988881011
Surprise %---------1.00%1.11%0.90%0.95%1.09%1.10%0.91%1.00%1.09%1.31%1.05%1.01%1.09%0.83%0.59%0.94%0.84%0.92%0.84%0.86%1.04%

Halozyme Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $231.00M, with a low forecast of $227.81M, and a high forecast of $237.20M. HALO's average Quarter revenue forecast represents a 6.93% increase compared to the company's last Quarter revenue of $216.03M (Sep 23).

Halozyme Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11136333685443435454599988881011
EBITDA---------$88.28M$115.09M$71.64M$79.06M$112.50M$46.61M$76.45M$57.64M$76.61M$94.00M$30.79M$79.08M$42.06M$31.70M$113.00K$-29.69M$-21.92M$-10.96M$6.01M$-21.48M$-26.64M
Avg Forecast$116.16M$111.64M$105.10M$99.51M$111.21M$95.34M$77.48M$96.90M$87.34M$81.69M$75.60M$88.10M$61.86M$68.69M$49.81M$80.09M$36.48M$38.03M$37.41M$38.97M$43.12M$21.52M$23.96M$124.30K$20.46M$19.75M$15.37M$6.01M$-24.41M$-25.57M
High Forecast$120.17M$115.50M$108.73M$101.49M$120.06M$96.72M$77.48M$116.29M$89.68M$88.89M$78.20M$105.71M$74.23M$68.69M$49.81M$96.10M$36.48M$38.03M$37.41M$46.76M$43.12M$21.52M$23.96M$149.16K$20.46M$19.75M$15.37M$7.22M$-19.53M$-20.46M
Low Forecast$113.21M$108.81M$102.43M$98.29M$105.10M$93.96M$77.48M$77.52M$86.13M$75.07M$73.67M$70.48M$49.48M$68.69M$49.81M$64.07M$36.48M$38.03M$37.41M$31.17M$43.12M$21.52M$23.96M$99.44K$20.46M$19.75M$15.37M$4.81M$-29.29M$-30.69M
Surprise %---------1.08%1.52%0.81%1.28%1.64%0.94%0.95%1.58%2.01%2.51%0.79%1.83%1.95%1.32%0.91%-1.45%-1.11%-0.71%1.00%0.88%1.04%

6 analysts predict HALO's average Quarter EBITDA for Dec 23 to be $87.34M, with a high of $89.68M and a low of $86.13M. This is -1.07% lower than Halozyme Therapeutics's previous annual EBITDA (Sep 23) of $88.28M.

Halozyme Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11136333685443435454599988881011
Net Income---------$81.84M$74.75M$39.62M$57.70M$61.63M$22.68M$60.11M$66.77M$216.59M$91.46M$27.89M$73.16M$36.21M$25.82M$-6.10M$-34.40M$-25.02M$-14.62M$1.80M$-27.46M$-32.90M
Avg Forecast$167.00M$153.12M$144.88M$134.04M$152.58M$124.67M$96.14M$75.70M$107.36M$91.90M$81.98M$68.82M$71.66M$46.74M$60.73M$62.56M$49.71M$54.72M$56.20M$35.30M$68.32M$25.16M$31.82M$-6.71M$-23.54M$-15.69M$-18.24M$1.80M$-31.21M$-31.58M
High Forecast$174.49M$159.99M$151.38M$135.30M$173.10M$127.66M$96.15M$90.84M$111.29M$98.19M$85.66M$82.58M$85.99M$46.74M$60.73M$75.07M$49.71M$54.72M$56.20M$42.37M$68.32M$25.16M$31.82M$-5.37M$-23.54M$-15.69M$-18.24M$2.16M$-24.96M$-25.26M
Low Forecast$161.49M$148.07M$140.10M$130.24M$142.32M$121.68M$96.12M$60.56M$103.43M$83.09M$79.28M$55.05M$57.32M$46.74M$60.73M$50.05M$49.71M$54.72M$56.20M$28.24M$68.32M$25.16M$31.82M$-8.06M$-23.54M$-15.69M$-18.24M$1.44M$-37.45M$-37.90M
Surprise %---------0.89%0.91%0.58%0.81%1.32%0.37%0.96%1.34%3.96%1.63%0.79%1.07%1.44%0.81%0.91%1.46%1.59%0.80%1.00%0.88%1.04%

Halozyme Therapeutics's average Quarter net income forecast for Dec 23 is $107.36M, with a range of $103.43M to $111.29M. HALO's average Quarter net income forecast represents a 31.19% increase compared to the company's last Quarter net income of $81.84M (Sep 23).

Halozyme Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11136333685443435454599988881011
SG&A---------$35.27M$38.95M$37.36M$37.75M$34.47M$57.48M$13.83M$13.77M$13.17M$12.32M$11.06M$10.43M$11.70M$10.97M$12.63M$23.93M$17.98M$17.34M$18.01M$13.56M$12.62M
Avg Forecast$66.12M$63.54M$59.82M$56.64M$63.30M$54.26M$44.10M$17.42M$49.71M$46.50M$43.03M$15.84M$14.78M$41.14M$29.83M$14.40M$21.85M$22.78M$22.40M$14.00M$25.82M$12.89M$14.35M$13.90M$12.25M$11.83M$9.20M$18.01M$15.40M$12.11M
High Forecast$68.40M$65.74M$61.88M$57.77M$68.33M$55.05M$44.10M$20.91M$51.04M$50.60M$44.51M$19.01M$17.74M$41.14M$29.83M$17.28M$21.85M$22.78M$22.40M$16.80M$25.82M$12.89M$14.35M$16.67M$12.25M$11.83M$9.20M$21.61M$18.49M$14.53M
Low Forecast$64.44M$61.93M$58.30M$55.94M$59.82M$53.48M$44.10M$13.94M$49.02M$42.73M$41.93M$12.67M$11.83M$41.14M$29.83M$11.52M$21.85M$22.78M$22.40M$11.20M$25.82M$12.89M$14.35M$11.12M$12.25M$11.83M$9.20M$14.40M$12.32M$9.69M
Surprise %---------0.76%0.91%2.36%2.55%0.84%1.93%0.96%0.63%0.58%0.55%0.79%0.40%0.91%0.76%0.91%1.95%1.52%1.88%1.00%0.88%1.04%

Halozyme Therapeutics's average Quarter SG&A projection for Dec 23 is $49.71M, based on 6 Wall Street analysts, with a range of $49.02M to $51.04M. The forecast indicates a 40.94% rise compared to HALO last annual SG&A of $35.27M (Sep 23).

Halozyme Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11136333685443435454599988881011
EPS---------$0.62$0.57$0.29$0.43$0.45$0.16$0.44$0.48$1.53$0.64$0.20$0.54$0.27$0.19$-0.04$-0.24$-0.17$-0.10$0.01$-0.19$-0.26
Avg Forecast$1.28$1.18$1.11$1.03$1.17$0.96$0.74$0.69$0.82$0.71$0.63$0.38$0.30$0.36$0.47$0.46$0.38$0.42$0.43$0.32$0.53$0.19$0.25$-0.02$-0.18$-0.12$-0.14$0.01$-0.25$-0.24
High Forecast$1.34$1.23$1.16$1.04$1.33$0.98$0.74$0.69$0.86$0.75$0.66$0.40$0.31$0.36$0.47$0.46$0.38$0.42$0.43$0.32$0.53$0.19$0.25$-0.02$-0.18$-0.12$-0.14$0.01$-0.20$-0.19
Low Forecast$1.24$1.14$1.08$1.00$1.09$0.94$0.74$0.69$0.79$0.64$0.61$0.37$0.29$0.36$0.47$0.46$0.38$0.42$0.43$0.32$0.53$0.19$0.25$-0.02$-0.18$-0.12$-0.14$0.01$-0.30$-0.29
Surprise %---------0.88%0.90%0.76%1.44%1.24%0.34%0.95%1.25%3.61%1.47%0.63%1.02%1.39%0.77%1.93%1.32%1.40%0.71%0.72%0.76%1.08%

According to 6 Wall Street analysts, Halozyme Therapeutics's projected average Quarter EPS for Dec 23 is $0.82, with a low estimate of $0.79 and a high estimate of $0.86. This represents a 33.06% increase compared to HALO previous annual EPS of $0.62 (Sep 23).

Halozyme Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
LRMRLarimar Therapeutics$4.32$17.00293.52%Buy
LEGNLegend Biotech$34.68$89.60158.36%Buy
ALECAlector$1.89$4.00111.64%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
RAREUltragenyx Pharmaceutical$44.95$90.00100.22%Buy
CYTKCytokinetics$47.78$90.0088.36%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
ASNDAscendis Pharma$140.30$211.1450.49%Buy
BGNEBeiGene$179.06$267.3349.30%Buy
PTGXProtagonist Therapeutics$40.69$57.3340.89%Buy
BMRNBioMarin Pharmaceutical$67.19$94.4340.54%Buy
AGIOAgios Pharmaceuticals$41.96$53.5027.50%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
INSMInsmed$73.85$87.5018.48%Buy
VRDNViridian Therapeutics$20.82$22.759.27%Buy
HALOHalozyme Therapeutics$48.60$52.007.00%Buy
EXELExelixis$34.69$30.89-10.95%Buy

HALO Forecast FAQ

Is Halozyme Therapeutics a good buy?

Yes, according to 9 Wall Street analysts, Halozyme Therapeutics (HALO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 66.67% of HALO's total ratings.

What is HALO's price target?

Halozyme Therapeutics (HALO) average price target is $52 with a range of $52 to $52, implying a 10.73% from its last price of $46.96. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Halozyme Therapeutics stock go up soon?

According to Wall Street analysts' prediction for HALO stock, the company can go up by 10.73% (from the last price of $46.96 to the average price target of $52), up by 10.73% based on the highest stock price target, and up by 10.73% based on the lowest stock price target.

Can Halozyme Therapeutics stock reach $70?

HALO's average twelve months analyst stock price target of $52 does not support the claim that Halozyme Therapeutics can reach $70 in the near future.

What are Halozyme Therapeutics's analysts' financial forecasts?

Halozyme Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $951.01M (high $978.07M, low $931.19M), average EBITDA is $380.94M (high $410.55M, low $354.07M), average net income is $449.09M (high $487.75M, low $420.68M), average SG&A $179.08M (high $188.39M, low $171.33M), and average EPS is $3.56 (high $3.74, low $3.45). HALO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.14B (high $1.18B, low $1.12B), average EBITDA is $432.42M (high $445.89M, low $422.74M), average net income is $599.05M (high $621.17M, low $579.9M), average SG&A $246.12M (high $253.78M, low $240.61M), and average EPS is $4.6 (high $4.77, low $4.46).

Did the HALO's actual financial results beat the analysts' financial forecasts?

Based on Halozyme Therapeutics's last annual report (Dec 2022), the company's revenue was $660.12M, beating the average analysts forecast of $650.11M by 1.54%. Apple's EBITDA was $310.68M, beating the average prediction of $260.44M by 19.29%. The company's net income was $202.13M, missing the average estimation of $241.69M by -16.37%. Apple's SG&A was $143.53M, beating the average forecast of $100.15M by 43.31%. Lastly, the company's EPS was $1.48, missing the average prediction of $1.59 by -7.02%. In terms of the last quarterly report (Sep 2023), Halozyme Therapeutics's revenue was $216.03M, missing the average analysts' forecast of $216.08M by -0.02%. The company's EBITDA was $88.28M, beating the average prediction of $81.69M by 8.06%. Halozyme Therapeutics's net income was $81.84M, missing the average estimation of $91.9M by -10.95%. The company's SG&A was $35.27M, missing the average forecast of $46.5M by -24.15%. Lastly, the company's EPS was $0.62, missing the average prediction of $0.706 by -12.20%